...
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma
【24h】

Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma

机译:甲状腺转录因子-1的表达是复发的独立预测因子,并与I期肺腺癌患者的IASLC / ATS / ERS组织学分类相关

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: In the current study, the authors investigated whether thyroid transcription factor-1 (TTF-1) expression is correlated with the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification and whether it stratifies patients with stage I lung adenocarcinoma with respect to disease recurrence. METHODS: Patients with stage I lung adenocarcinoma were classified according to the IASLC/ATS/ERS classification. Tissue microarrays were constructed and immunostaining for TTF-1 was performed. A total of 452 cases were available for analysis. Tumors were dichotomized based on the intensity of nuclear TTF-1 expression as negative (score of 0) or positive (score of 13). The cumulative incidence of recurrence (CIR) was used to estimate disease recurrence probabilities. RESULTS: TTF-1 expression was identified in 92% of patients, including 100% of patients with minimally invasive or lepidic-predominant adenocarcinoma, 94% of patients with acinar-predominant adenocarcinoma, 98% of patients with papillary-predominant adenocarcinoma, 93% of patients with micropapillary-predominant adenocarcinoma, 86% of patients with solid-predominant adenocarcinoma, 67% of patients with colloid-predominant adenocarcinoma, and 47% of patients with invasive mucinous carcinoma. The CIR for patients with negative TTF-1 expression (n = 34 patients; 5-year CIR, 40%) was significantly higher than that for patients with positive TTF-1 expression (n = 418 patients; 5-year CIR, 15%) (P < .001). Among the patients with intermediate-grade tumors, the CIR for patients with negative TTF-1 expression (n = 16 patients; 5-year CIR, 45%) was significantly higher than that for patients with positive TTF-1 expression (n = 313 patients; 5-year CIR, 14%) (P < .001). On multivariate analysis, negative TTF-1 expression was found to be significantly correlated with an increased risk of disease recurrence (hazards ratio, 2.55; P = .009). CONCLUSIONS: TTF-1 expression was found to be an independent predictor of disease recurrence, stratifying intermediate-grade tumors into 2 prognostic subsets, and it correlates with the IASLC/ATS/ERS classification. Cancer 2013. (c) 2012 American Cancer Society.
机译:背景:在当前的研究中,作者调查了甲状腺转录因子-1(TTF-1)的表达是否与国际肺癌研究协会(IASLC)/美国胸腔学会(ATS)/欧洲呼吸学会(ERS)相关)分类,以及在疾病复发方面是否对I期肺腺癌患者进行分层。方法:根据IASLC / ATS / ERS分类对I期肺腺癌患者进行分类。构建组织微阵列,并对TTF-1进行免疫染色。共有452个案例可供分析。根据核TTF-1表达的强度将肿瘤分为阴性(0分)或阳性(13分)。复发的累积发生率(CIR)用于估计疾病的复发概率。结果:在92%的患者中鉴定出TTF-1表达,其中100%的患者为微浸润性或鳞状细胞性腺癌,94%的患者为腺泡性腺癌,98%的患者为乳头状腺癌,93%微乳头状为主的腺癌患者,86%的以固体为主的腺癌患者,67%的以胶体为主的腺癌患者和47%的浸润性黏液癌患者。 TTF-1表达阴性的患者(n = 34患者; 5年CIR,40%)的CIR显着高于TTF-1表达阳性的患者(n = 418患者; 5年CIR,15%) )(P <.001)。在中度肿瘤患者中,TTF-1表达阴性的患者(n = 16; 5年CIR,45%)的CIR明显高于TTF-1表达阳性的患者(n = 313)患者; 5年CIR,14%)(P <.001)。在多变量分析中,发现TTF-1阴性表达与疾病复发风险显着相关(危险比,2.55; P = .009)。结论:发现TTF-1表达是疾病复发的独立预测因子,将中级肿瘤分为2个预后亚组,并且与IASLC / ATS / ERS分类相关。癌症,2013年。(c)2012年美国癌症协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号